KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Prepaid Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Prepaid Assets for 13 consecutive years, with $150.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Prepaid Assets changed N/A to $150.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $150.7 million, a N/A change, with the full-year FY2024 number at $39.0 million, down 19.88% from a year prior.
  • Prepaid Assets was $150.7 million for Q3 2025 at Halozyme Therapeutics, up from $39.0 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $150.7 million in Q3 2025 to a low of $39.0 million in Q4 2024.
  • A 3-year average of $75.1 million and a median of $55.4 million in 2023 define the central range for Prepaid Assets.
  • Biggest YoY gain for Prepaid Assets was 19.88% in 2024; the steepest drop was 19.88% in 2024.
  • Halozyme Therapeutics' Prepaid Assets stood at $48.6 million in 2023, then fell by 19.88% to $39.0 million in 2024, then soared by 286.78% to $150.7 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Prepaid Assets are $150.7 million (Q3 2025), $39.0 million (Q4 2024), and $48.6 million (Q4 2023).